EVOLVE: Difference between revisions

Jump to navigation Jump to search

EVOLVE (view source)

Revision as of 17:57, 15 October 2015

645 bytes removed ,  15 October 2015
simplify funding
(simplify funding)
Line 38: Line 38:


==Guidelines==
==Guidelines==
'''KDIGO CKD-BMD''' (2009, adapted)<ref name="kdigo">[http://www.kdigo.org/clinical_practice_guidelines/pdf/CKD/KDIGO%20CKD-MBD%20GL%20KI%20Suppl%20113.pdf Kidney Disease: Improving Global Outcomes (KDIGO) CKD–MBD Work Group. "KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease–mineral and bone disorder (CKD–MBD)." ''Kidney International.'' 2009; 76 (Suppl 113): S1–S130.]</ref>
'''KDIGO CKD-BMD''' (2009, adapted)<ref name="kdigo/">


''These guidelines reflect the outcomes of the EVOLVE trial. The working group of the 2013 KDIGO Controversies Conference did not make changes to the 2009 recommendations.''<ref name="ketteler">[http://www.kdigo.org/ControConf/CKD-MBD%202013/KDIGO%202013%20CKD-MBD%20Controversies%20Conf%20Report%20AOP.pdf Ketteler M, et al. "Revisiting KDIGO clinical practice guideline on chronic kidney disease—mineral and bone disorder: a commentary from a Kidney Disease: Improving Global Outcomes controversies conference." ''Kidney International. ''2014.]</ref>
''These guidelines reflect the outcomes of the EVOLVE trial. The working group of the 2013 KDIGO Controversies Conference did not make changes to the 2009 recommendations.''<ref name="ketteler">[http://www.kdigo.org/ControConf/CKD-MBD%202013/KDIGO%202013%20CKD-MBD%20Controversies%20Conf%20Report%20AOP.pdf Ketteler M, et al. "Revisiting KDIGO clinical practice guideline on chronic kidney disease—mineral and bone disorder: a commentary from a Kidney Disease: Improving Global Outcomes controversies conference." ''Kidney International. ''2014.]</ref>
Line 193: Line 193:
** Cinacalcet hypothesized to primarily effect non-atherosclerotic endpoints (slowing arterial calcification, reducing myocardial calcium accumulation)<ref>[http://www.ncbi.nlm.nih.gov/pubmed/25404192 Wheeler DC, et al. "Effects of Cinacalcet on Atherosclerotic and Nonatherosclerotic Cardiovascular Events in Patients Receiving Hemodialysis: The Evaluation Of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial". ''J Am Heart Assoc. ''2014;3:e001363.]</ref>
** Cinacalcet hypothesized to primarily effect non-atherosclerotic endpoints (slowing arterial calcification, reducing myocardial calcium accumulation)<ref>[http://www.ncbi.nlm.nih.gov/pubmed/25404192 Wheeler DC, et al. "Effects of Cinacalcet on Atherosclerotic and Nonatherosclerotic Cardiovascular Events in Patients Receiving Hemodialysis: The Evaluation Of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial". ''J Am Heart Assoc. ''2014;3:e001363.]</ref>


==Funding==<!-- remove when cleared by an editor -->
==Funding==
* Amgen (manufacturer of Cinacalcet) provided
* Amgen (the manufacturer of Cinacalcet) was significantly involved.
** Representatives of Amgen as nonvoting members were placed on the executive committee
** Amgen collected and analyzed trial data to a predefined statistical analysis plan
** Analyses were verified by independent statisticians


==Further Reading==
==Further Reading==
Diberri
Bureaucrats, editor, reviewer, Administrators
5,246

edits

Retrieved from "http://www.wikijournalclub.org/wiki/Special:MobileDiff/18575"

Navigation menu